Colorectal cancer (CRC) is the third most frequent cancer worldwide, ranking second in cancer-related mortality.1,2 Metastasis, accounting for up to 90% of cancer-related deaths, is still the most incomprehensible part of cancer progression.3 Evidence is mounting that epithelial–mesenchymal transition (EMT) initiates the metastatic progression of CRC.4–6 EMT is a transdifferentiation process, that is associated with enhanced tumour dissemination, disruptions the apical-basal polarity, decreased numbers of cellular junctions, and EMT requires the reduction of E-cadherin expression. The gene discussed is CDH1; the disease is colorectal carcinoma.